Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
aTyr Pharma, Inc. (ATYR)
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 8, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATYR PHARMA INC. (ATYR), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.What Happened?On September 15, 2025, aTyr announced that the Phase 3 study of its intravenous Efzofitimod pulmonary sarcoidosis treatment, EFZO-FIT, did not meet its primary endpoint in change from baseline in mean daily OSC dose at week 48.On this news, aTyr’s stock price fell $5.01, or 83.2%, to close at $1.02 per share on September 15, 2025, thereby injuring investors.What Is The Lawsuit About?The complaint filed in this class action alleges that throughout the Class
Show less
Read more
Impact Snapshot
Event Time:
ATYR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATYR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATYR alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATYR
News
- aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary SarcoidosisGlobeNewswire
- Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) ShareholdersPR Newswire
- Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) ShareholdersGlobeNewswire
- ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud LawsuitPR Newswire
ATYR
Earnings
- 11/6/25 - Miss
ATYR
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- ATYR's page on the SEC website